Year in Review — Multiple Myeloma: 2007-2008
About Year in Review
Year in Review is a unique CME activity that attempts to distill the more than 300 data sets and journal articles in multiple myeloma published in 2007-2008 into a convenient summary of the most clinically relevant papers and presentations. Four myeloma clinical investigators and 25 community oncologists rated each of the aforementioned myeloma articles and presentations based on importance and potential to impact clinical practice. The top 25 papers as determined by these ratings were then divided into two categories — “essential for all oncologists” and “recommended but not crucial to patient care” and are included in Year in Review. Each selected paper is presented as a slide summary highlighting the key findings. Case-based questions that correspond to the papers are also included to enhance didactic presentations and self-directed learning. For a complete overview of the comprehensive vetting process used to select the papers for inclusion in Year in Review, please consult the Editor’s Note.
EDITOR
Neil Love, MD
FACULTY
Andrzej J Jakubowiak, MD, PhD
Sagar Lonial, MD
Robert Z Orlowski, MD, PhD
Paul G Richardson, MD
EDITOR'S NOTE
Year in Review
Michele Cavo et al. Prospective, randomized study of single
compared with double autologous stem-cell transplantation
for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25(17):2434-41.
Jeffrey A Zonder et al. Superiority of lenalidomide (Len) plus
high-dose dexamethasone (HD) compared to HD alone as treatment
of newly-diagnosed multiple myeloma (NDMM): Results of
the randomized, double-blinded, placebo-controlled SWOG Trial
S0232. Proc ASH 2007.
Amitabha Mazumder et al. The effect of induction therapy with novel
agents on stem cell mobilization in multiple myeloma. Proc ASCO 2007.
Marco Ladetto et al. Consolidation with bortezomib, thalidomide
and dexamethasone induces molecular remissions in autografted
multiple myeloma patients. Proc ASH 2007.
Cyrille Hulin et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates
a significant survival advantage in elderly patients ≥ 75
years with multiple myeloma compared with melphalan-prednisone
(MP) in a randomized, double-blind, placebo-controlled trial, IFM
01/01. Proc ASH 2007.
Paul G Richardson et al. Safety and efficacy of bortezomib in high-risk
and elderly patients with relapsed multiple myeloma. Br J
Haematol 2007;137(5):429-35.
Jesus F San-Miguel et al. Efficacy and safety of bortezomib in
patients with renal impairment: Results from the APEX phase 3
study. Leukemia 2008;22(4):842-9.
Paul G Richardson et al. Extended follow-up of a phase 3 trial in
relapsed multiple myeloma: Final time-to-event results of the
APEX trial. Blood 2007;110(10):3557-60.
Bart Barlogie et al. Incorporating bortezomib into up-front treatment
for multiple myeloma: Early results of total therapy 3. Br J Haematol 2007;138(2):176-85.
Rakesh Popat et al. Bortezomib, doxorubicin and dexamethasone
(PAD) front-line treatment of multiple myeloma: Updated results
after long-term follow-up. Br J Haematol 2008;141(4):512-6.
Antonio Palumbo et al. Melphalan, prednisone, and lenalidomide
treatment for newly diagnosed myeloma: A report from
the GIMEMA — Italian Multiple Myeloma Network. J Clin Oncol 2007;25(28):4459-65.
Antonio Palumbo et al. Prevention of thalidomide- and lenalidomide-associated
thrombosis in myeloma. Leukemia 2008;22(2):414-23.
Ashraf Badros et al. Neurotoxicity of bortezomib therapy in multiple
myeloma: A single-center experience and review of the literature. Cancer 2007;110(5):1042-9.
Verena Sagaster et al. Bortezomib in relapsed multiple myeloma:
Response rates and duration of response are independent of a
chromosome 13q-deletion. Leukemia 2007;21(1):164-8.
CLINICAL CASE SCENARIOS AND POLL QUESTIONS
